Navigation Links
A new model for studying Parkinson's
Date:2/1/2011

s a large and complicated enzyme and designing a vector capable of transporting its extremely long genetic code was no small feat.

The new animal model developed by EPFL is sure to benefit future Parkinson's research. The fact that LRRK2 is an enzymea catalyzing protein involved in chemical reactionsmakes it drug accessible and therefore of specific interest to researchers looking for neuroprotective strategies, or pharmaceutical treatments that halt or slow disease progression by protecting vulnerable neurons. Armed with the LRRK2 model, new pharmaceuticals that inhibit the hyper-activity of the enzyme could one day prevent the destructive chain of events that leads to neurodegeneration and devastation in many with PD.


'/>"/>

Contact: Michael Mitchell
michael.mitchell@epfl.ch
41-798-103-107
Ecole Polytechnique Fdrale de Lausanne
Source:Eurekalert  

Page: 1 2

Related biology technology :

1. Model Predicts a Drugs Likelihood of Causing Birth Defects
2. INTERCIM Received a New Patent for a Non-statistical Approach for "Design of Experiments" and the Iterative Discovery of an Explanatory Model
3. Intra-Cellular Therapies Announces Positive Results with ITI-002 in Pre-Clinical Models of Parkinsons Disease
4. New hydrolysis model promising tool in cellulosic biofuel studies
5. MD Biosciences Offers Occlusion-induced Myocardial Infarct Model for Investigating the Cardio-protection of a Drug Treatment in the Event of Ischemia/reperfusion Injury
6. Jeffrey Mogil to Speak on Animal Models of Pain at Arrowhead's 4th Annual Pain Therapeutics Summit
7. Zymes’ Water Soluble CoQ10 Decreases Symptoms in Animal Models of Parkinson’s Disease
8. Zenith Biotech Introducing Novel StemQ(R) Hepatic and Neural Models for Use in Drug Discovery, Metabolism and Toxicology Studies, at The 49th Annual Meeting and ToxExpo In Salt Lake City, Utah, March 7-11, 2010, Booth #136
9. Model N Extends its Industry-Leading Contract Management Offerings with Contract Authoring Capabilities
10. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING
11. Biomodels Scientists Report Development of a Novel Model for Cancer Treatment-Related Fatigue
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
A new model for studying Parkinson's
(Date:8/1/2014)... August 01, 2014 Once a decision ... cost? This webinar will discuss how to define your ... Join speakers Bob Allen, Senior Director of Facilities Integration ... Engineering at Fluor Industrial Services, and special guest Carrier ... Planning at Amgen, as they provide an examination of ...
(Date:8/1/2014)... -- Cambrex Corporation (NYSE: CBM ) reports results ... Highlights , Second quarter sales increased 59% ... last year. , Second quarter EBITDA increased 86% to ... last year (see table at the end of this release). ... impact of foreign currency, to between 13% and 16% over ...
(Date:8/1/2014)... ON (PRWEB) August 01, 2014 ... has led to a better understanding embryonic development. ... and reorganize into structurally and functionally distinct tissues ... physical defects. Prof. Todd McDevitt, Melissa Kinney, ... biophysical signals interact with biochemical cues to control ...
(Date:7/31/2014)... August 01, 2014 “2014 ... Polyurethane Resin Industry” is a professional and ... The report introduces Polyurethane Resin basic information, ... chain structure and industry overview. This research ... domestic market as well as global industry ...
Breaking Biology Technology:Defining Low Cost in Your Solution for Future Facilities, New Webinar for Pharma, Biotech, Medical Device and Healthcare Companies, Hosted by Xtalks 2Cambrex Reports Second Quarter 2014 Financial Results 2Cambrex Reports Second Quarter 2014 Financial Results 3Cambrex Reports Second Quarter 2014 Financial Results 4Cambrex Reports Second Quarter 2014 Financial Results 5Cambrex Reports Second Quarter 2014 Financial Results 6Cambrex Reports Second Quarter 2014 Financial Results 7Cambrex Reports Second Quarter 2014 Financial Results 8Cambrex Reports Second Quarter 2014 Financial Results 9Cambrex Reports Second Quarter 2014 Financial Results 10Cambrex Reports Second Quarter 2014 Financial Results 11Cambrex Reports Second Quarter 2014 Financial Results 12Cambrex Reports Second Quarter 2014 Financial Results 13Cambrex Reports Second Quarter 2014 Financial Results 14Cambrex Reports Second Quarter 2014 Financial Results 15Cambrex Reports Second Quarter 2014 Financial Results 16Study Links Biomechanics and Gene Expression in Stem Cells 2Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 2Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 3Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 4
... Timing of Final Analysis by One, Year While Maintaining Comparable Powering ... March 13, 2008 at 11:00 AM ... ... DNDN ) today announced that the U.S. Food and Drug Administration,(FDA) has ...
... to Improve Healing ... of ... Americas,a healthcare company focused on improving patient quality of life, ... mark for its KFH Novo medical device, a breakthrough medical,technology ...
... EMERYVILLE, Calif., March 11 Onyx,Pharmaceuticals, Inc. (Nasdaq: ... present,at the Cowen and Company 28th Annual Health ... Eastern Time. Interested parties may access a live,webcast ... is recommended that listeners log on 15 minutes ...
Cached Biology Technology:FDA Agrees to Amend Dendreon's Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE 2FDA Agrees to Amend Dendreon's Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE 3FDA Agrees to Amend Dendreon's Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE 4Kingfisher Healthcare Receives European CE Mark for Next Generation Wound Healing Device 2
(Date:8/1/2014)... examining a taxonomically confused group of marine mammals ... the Australian humpback dolphin, Sousa sahulensis , ... Enterprises. , The study describing the newly ... long systematic examination of all available historical records, ... widespread group of coastal cetaceans ranging from the ...
(Date:8/1/2014)... enormous opportunities for both biological and future clinical ... cells in the body, offering immense hope of ... kidney, liver and lung diseases and making damaged ... Prof. Jinhui Chen from Indiana University in USA ... myriad biological, ethical, legal, political, and financial challenges. ...
(Date:8/1/2014)... INDIANAPOLIS, IN August 1, 2014 The Journal ... Best Article and Best Great Educational Material (GEM) awards, ... and Behavior (SNEB) annual conference, "Nutrition Education Impact: Local ... 1, 2014. These annual awards recognize the authors ... year in JNEB, as judged by members of the ...
Breaking Biology News(10 mins):Scientists name new species of cetacean: The Australian humpback dolphin 2Scientists name new species of cetacean: The Australian humpback dolphin 3
... 2012Epstein-Barr virus (EBV) is the cause of infectious mononucleosis ... recipients. Molecular tests that can identify early protein markers ... infection. The benefits of this diagnostic approach in patients ... in an article published in BioResearch Open Access ...
... November 13, 2012Following an infection, dysregulation of the immune ... an often fatal condition called severe sepsis or septic ... underlying immune dysfunction remain poorly understood. Regulatory T cells ... to have an important role in suppressing the immune ...
... Come rain or shine (or even snow), some glaciers ... to come. The forecast by Brigham Young University ... Bhutan, a region in the bull,s-eye of the monsoonal ... most conservative findings indicate that even if climate remained ...
Cached Biology News:Are we closer to understanding the cause of deadly sepsis? 2Himalayan glaciers will shrink even if temperatures hold steady 2
UltraMount is formulated for coverslipping sections stained with alcohol soluble chromogens, such as Fast-Red or AEC. No heating is required prior to use. Coverslips may be removed by soaking in wate...
Agarose, Biotechnology grade, 500g...
AM100 is an aqueous-based, permanent mounting media designed for use with alkaline phosphatase and immunoperoxidase stained tissue sections....
... c-Jun proto-oncogene was first identified as the cellular ... Jun B and Jun D have been shown ... C-terminal regions, which are involved in dimerization and ... involved in transcriptional activation, diverge. ...
Biology Products: